CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data

Advances in Experimental Medicine and Biology

Volumn 519, Issue , 2003, Pages 145-153

  Inoue, Kazuhiro ^a   Kumazawa, Eiji ^a   Kuga, Hiroshi ^a   Susaki, Hiroshi ^a   Masubuchi, Noriko ^a   Kajimura, Tetsuyo ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; CARBOXYMETHYLDEXTRAN; DE 310; DRUG CARRIER; EXATECAN; POLYOL;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; CANCER MODEL; CONFERENCE PAPER; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG SYNTHESIS; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ALCOHOLS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; DEXTRANS; DOGS; DRUG DESIGN; INJECTIONS, INTRAVENOUS; MICE; POLYMERS; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0037619162     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (16)

1. Ringsdorf, H., 1975, Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 20: 135-153.
2. Matsumura, Y., and Maeda, H., 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism and antitumor agent smancs. Cancer Res. 46: 6387-6392.
3. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., and Hori, K., 2000, Tumor vascular permeability and EPR effect in macromolecular therapeutics: a review. J. Control. Release 65: 271-284.
4. Maeda, H., 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advan. Enzyme Regul. 41: 189-207.
5. Duncan, R., Seymour, L.W., O'Hare, K.B., Flanagan, P.A., Wedge, S., Hume, I.C., Ulbrich, K., Strohalm, J., Subr, V., Spareafico, F., Grandi, M., Ripamonti, M., Farao, M., and Suarato, A., 1992, Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release 19: 331-346.
6. Vasey, P.A., Twelves, C., Kaye, S.B., Wilson, P., Morrison, R., Duncan, R., Thomson, A., Murray, L., Hilditch, T.E., Murray, T., Burtles, S., Frigerio, E., Fraier, D., and Cassidy, J., 1998, Phase I clinical and pharmacokinetic study of PK1. Abstructs of 3rd International Symposium on Polymer Therapeutics, p. 21.
7. Inoue, K., Okuno, S., Hamana, H., and Ito, T., 1993, Glyco-technology and DDS. FARUMASHIA 29: 1256-1260.
8. Nogusa, H., Yano, T., Okuno, S., Hamana, H., and Inoue, K., 1995, Synthesis of carboxymethylpullulan-peptide-doxorubicin conjugates and their properties. Chem. Pharm. Bull. 43: 1931-1938.
9. Sugawara, S., Okuno, S., Yano, T., Hamana, H., and Inoue, K., 2001, Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol. Pharm. Bull. 24: 535-543.
10. Goldstein, I.J., Hay, G.W., Lewis, A., and Smith, F., 1965, Controlled degradation of polysaccharides by periodate oxidation, reduction, and hydrolysis. Methods in Carbohydr. Chem. 5: 361-370.
11. Kumazawa, E., and Tohgo, A., 1998, Antitumor activity of DX-8951f: a new camptothecin derivative. Exp. Opin. Invest. Drugs. 7: 625-632.
12. Kumazawa, E., Ochi, Y., Tanaka, N., Kajimura, T., and Inoue, K., 2001, A novel macromolecular carrier system for the camptothecin analog DX-8951f [I]: its antitumor activities in the murine Meth A solid tumor model. Proc. Am. Assoc. for Cancer Res. 42: 139.
13. Ochi, Y., Kumazawa, E., Nakata, M., Tanaka, N., and Inoue, K., 2001, A novel macromolecular carrier system for the camptothecin analog DX-8951f [II]: its antitumor activities in several model systems of human and murine tumors. Proc. Am. Assoc. for Cancer Res. 42: 376.
14. Masubuchi, N., Gohda, R., Seki, H., Hayashi, K., Atsumi, R., and Inoue, K., 2001, A novel macromolecular carrier system for the camptothecin analog DX-8951f [III]: pharmacokinetic evaluation in normal and tumor-bearing mice. Proc. Am. Assoc. for Cancer Res. 42: 376.
15. Soepenberg, O., De Jonge, M.J.A., Loos, W.J., Sparreboom, A., Eskens, F.A.L.M., De Heus, G., Elliott, S., Cheverton, P., Bastien, L., and Verweij, J., 2002, Phase I and pharmacologic study of the macromolecular topoisomerase-I-inhibitor DE-310 given once every 2 or 6 weeks in patients with solid tumors. Eur. J. Cancer (Suppl. 7) 38: S45.
16. Takimoto, C.H., Forero, F., Schwartz, G.H., Tolcher, A.W., Hammond, L.A., Patnaik, A., Ducharme, M., Cooke, B., De Jager, R., and Rowinsky, E.K., 2002, A phase I and pharmacokinetic study of DE-310 administered as a 3 hour infusion every 4 weeks (wks) to patients (pts) with advanced solid tumors or lymphomas. Eur. J. Cancer (Suppl. 7) 38: S46.